Source: Postgraduate course 2021: PG7 - Postgraduate course : Emerging infectious diseases and antimicrobial resistance: diagnostics, treatments, vaccines and other preventive and/or therapeutic interventions



Rating:

Share or cite this content

Citations should be made in the following way:
Maurizio Sanguinetti (Rome, Italy). Improved diagnostics and diagnostic approaches: The role in the fight to emerging infectious diseases (EID) and antimicrobial resistance (AMR). Postgraduate course 2021: PG7 - Postgraduate course : Emerging infectious diseases and antimicrobial resistance: diagnostics, treatments, vaccines and other preventive and/or therapeutic interventions

Member's Comments

No comment yet.

Related content which might interest you: From the bedside: upcoming new clinical strategies: novel strategies to combat respiratory viral infections Source: International Congress 2017 – Scientific year in review Year: 2017 CF microbiology, emerging pathogens and more treatment options Source: Annual Congress 2013 –PG20 Cystic fibrosis: an update of the basic defects and clinical problems in CF children and adults Year: 2013 Advances in the diagnosis of mycobacteria infections and challenges of drug susceptibility testing Source: International Congress 2019 – New guidelines for treatment of nontuberculous mycobacterial pulmonary disease Year: 2019 The challenges of severe pneumonia: new pathogens, new drugs and new formulations Source: Virtual Congress 2021 – Respiratory infections Year: 2021 Host transcriptomics for diagnosis of infectious diseases: one step closer to clinical application Source: Eur Respir J, 49 (6) 1700993; 10.1183/13993003.00993-2017 Year: 2017 Non-pharmacological factors for the emergence of drug resistance in patients of pulmonary tuberculosis: An Indian overview Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Challenges and perspectives for improved management of HIV/Mycobacterium tuberculosis co-infection Source: Eur Respir J 2010; 36: 1242-1247 Year: 2010 The impact and cost-effectiveness of strategies to detect drug-resistant tuberculosis Source: Eur Respir J 2012; 39: 626-634 Year: 2012 Emerging and re-emerging infectious diseases: a continuous challenge for Europe Source: Eur Respir J 2012; 40: 1312-1314 Year: 2012 Antibiotic resistance in respiratory infections: challenges and actions for the upcoming decade Source: Virtual Congress 2021 – Respiratory infections Year: 2021 Fate or missed opportunities - challenges in diagnosing paediatric drug resistant tuberculosis in Germany Source: Virtual Congress 2021 – Paediatric respiratory infections: chronic infection, vaccination and lung function Year: 2021 Strategies against multidrug-resistant tuberculosis Source: Eur Respir J 2002; 20: 66S-77S Year: 2002 Update on management of new emerging acute respiratory viral infectious diseases Source: International Congress 2018 – Chinese Programme 2018: Part I Year: 2018 COVID-19 vaccines: immunology, regulation and clinical management Source: Eur Respir Monogr 2021; 94: 244-260 Year: 2021 Use of molecular-genetic methods in diagnostics and therapy of a tuberculosis (TB) at patients with HIV Source: Annual Congress 2010 - Tuberculosis in special populations Year: 2010 Economic aspects of enhanced testing strategies for respiratory diseases Source: Value-Dx event 2021: Community-acquired respiratory tract infections: where do we stand in 2021, ECCMID 2021 Year: 2021 Antibody and host inflammatory biomarker combinations as diagnostic tools for TB disease Source: International Congress 2017 – Update on TB: latest news Year: 2017 Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19 Source: Eur Respir J, 55 (6) 2000858; 10.1183/13993003.00858-2020 Year: 2020 “Procalcitonin in respiratory disease: use as a biomarker for diagnosis and guiding antibiotic therapy” Breathe 2019; 15: 296–304. Source: Breathe, 15 (4) e152; 10.1183/20734735.5258-2019 Year: 2019